13.49
-0.66(-4.66%)
Currency In USD
Address
100 Cambridgepark Drive
Cambridge, MA 02140
United States of America
Phone
617 655 6580
Website
Sector
Healthcare
Industry
Biotechnology
Employees
159
First IPO Date
February 05, 2021
| Name | Title | Pay | Year Born |
| Jean-Paul Kress | Chairman & Chief Executive Officer | 0 | 1965 |
| Jeremy Sokolove | Chief Medical Officer | 695,160 | N/A |
| Robert Ang | Strategic Advisor | 994,049 | 1975 |
| Navid Z. Khan | Chief Medical Affairs Officer | 0 | N/A |
| Qing Zuraw | Chief Development Officer | 0 | N/A |
| Siddhartha Mukherjee | Scientific Founder & Chairman of Scientific Advisory Board | 0 | 1971 |
| Dallan Murray | Chief Commercial Officer | 0 | 1970 |
| Sandesh Mahatme | Chief Business Officer & Chief Financial Officer | 0 | 1965 |
| Adi Osovsky | General Counsel | 0 | N/A |
| Tania Philipp | Chief People Officer | 0 | 1972 |
Vor Biopharma, Inc., a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company's VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells. The company's eHSCs targeted therapies, such as CAR-Ts, bispecific antibodies, and antibody-drug conjugates provide treatment for blood cancers. Vor Biopharma, Inc. has a collaboration agreement with Akron BioProducts to develop and manufacture cGMP nucleases. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.